Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.46 |
| ▸ | AXL | P30530 | 1/20 | 0.40 |
| ▸ | EP300 | Q09472 | 1/20 | 0.40 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.40 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.40 |
| ▸ | NOS3 | P29474 | 4/20 | 0.38 |
| ▸ | NOS2 | P35228 | 4/20 | 0.38 |
| ▸ | NOS1 | P29475 | 2/20 | 0.38 |
| ▸ | ABL1 | P00519 | 1/20 | 0.38 |
| ▸ | FYN | P06241 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | CLK1 | P49759 | 1/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.37 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25899016 | 0.84 | NOS2 (0.47) | TBK1AXLEP300KAT2BKAT8 | |
| SCHEMBL18266939 | 0.79 | HIPK2 (0.37) | AXLEP300KAT2BKAT8LMNA | |
| SCHEMBL12070709 | 0.77 | PLAU (0.52) | NOS3NOS2NOS1CYP1A2PLAU | |
| SCHEMBL25323051 | 0.76 | TBK1 (0.46) | TBK1AXLEP300KAT2BKAT8 | |
| SCHEMBL12440236 | 0.76 | AXL (0.58) | TBK1AXLEP300KAT2BKAT8 | |
| SCHEMBL13219620 | 0.76 | EP300 (0.40) | AXLEP300KAT2BKAT8LMNA | |
| SCHEMBL18266941 | 0.75 | CCR1 (0.35) | AXLEP300KAT2BKAT8LMNA | |
| SCHEMBL21436749 | 0.75 | AXL (0.52) | TBK1AXLEP300KAT2BKAT8 | |
| SCHEMBL17571743 | 0.73 | AXL (0.60) | AXLEP300KAT2BKAT8LMNA | |
| SCHEMBL812489 | 0.73 | CYP1A2 (0.46) | AXLEP300KAT2BKAT8LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023146990-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023146991-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023146987-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| US-9382244-B2 | 7-azaindole-2,7-naphthyridine derivative for the treatment of tumours | MERCK PATENT GMBH (DE) | 2016-07-05 | — | — | US | disclosed |
| US-20150252041-A1 | 7-AZAINDOLE-2,7-NAPHTHYRIDINE DERIVATIVE FOR THE TREATMENT OF TUMOURS | MERCK PATENT GMBH (DE) | 2015-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150252041-A1 | 7-AZAINDOLE-2,7-NAPHTHYRIDINE DERIVATIVE FOR THE TREATMENT OF TUMOURS | MKI67, TK2, TYMP | TBK1 392/4885AXL 2291/4885EP300 2116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.